Guardado-Mendoza R, Salazar-López SS, Álvarez-Canales M, et al. - In this single center parallel double-blind randomized clinical trial with 24 months of follow-up, researchers assessed the impact of the combination of lingaliptin + metformin + lifestyle on glucose tolerance, pancreatic β-cell function and T2D incidence in patients with prediabetes. The sample consisted of patients with impaired glucose tolerance plus two T2D risk factors which were randomized to linagliptin 5 mg + metformin 1,700 mg daily + lifestyle (LM group) or metformin 1,700 mg daily + lifestyle (M group). The combination of linagliptin, metformin, and lifestyle significantly improved glucose metabolism and pancreatic β-cell function and decreased T2D incidence in prediabetes subjects compared with metformin and lifestyle. During the study, no major side effects were observed.